Lemaitre Vascular Inc (LMAT) — SEC Filings
Lemaitre Vascular Inc (LMAT) — 37 SEC filings. Latest: DEFA14A (Apr 14, 2026). Includes 16 8-K, 6 10-Q, 6 SC 13G/A.
View Lemaitre Vascular Inc on SEC EDGAR
Overview
Lemaitre Vascular Inc (LMAT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 14, 2026: On April 8, 2026, Lemaître Vascular, Inc. announced the appointment of David L. Roberts as Chief Financial Officer, effective April 15, 2026. Roberts will receive an annual base salary of $350,000 and is eligible for a discretionary annual bonus. He will also be granted 50,000 restricted stock units
Sentiment Summary
Across 37 filings, the sentiment breakdown is: 6 bullish, 31 neutral. The dominant filing sentiment for Lemaitre Vascular Inc is neutral.
Filing Type Overview
Lemaitre Vascular Inc (LMAT) has filed 2 DEFA14A, 16 8-K, 1 ARS, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (37)
Risk Profile
Risk Assessment: Of LMAT's 29 recent filings, 0 were flagged as high-risk, 6 as medium-risk, and 23 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $61.046M |
| Net Income | $17.362M |
| EPS | $0.77 |
| Cash Position | $25.494M |
Key Executives
- David L. Roberts
- Donald Trump
- David M. D’Amato
- Dr. David E. Astion
- George W. LeMaitre
Industry Context
LEMAITRE VASCULAR INC operates in the highly competitive medical device industry, specifically focusing on vascular devices. The sector is characterized by continuous innovation, stringent regulatory oversight, and the need for strong clinical evidence to support product adoption. Key trends include the development of minimally invasive technologies and increasing demand for specialized treatments in cardiovascular and peripheral vascular diseases.
Top Tags
sec-filing (5) · financial-reporting (5) · medical-devices (4) · Medical Devices (3) · 10-Q (3) · financials (3) · executive-compensation (3) · amendment (3) · institutional-ownership (3) · annual-report (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| CFO Base Salary | $350,000 | Annual compensation for David L. Roberts |
| RSUs Granted | 50,000 | Stock units awarded to the new CFO vesting over three years |
| ARS Document Size | 1172228 | The size of the primary ARS document in bytes. |
| Submission Text File Size | 1613109 | The size of the complete submission text file in bytes. |
| Net Sales (Q3 2025) | $61.046M | Increased 11.3% from $54.819M in Q3 2024 |
| Net Income (Q3 2025) | $17.362M | Increased 55.8% from $11.141M in Q3 2024 |
| Net Sales (9 months 2025) | $185.149M | Increased 12.8% from $164.146M in 9 months 2024 |
| Net Income (9 months 2025) | $42.152M | Increased 28.3% from $32.854M in 9 months 2024 |
| Basic EPS (Q3 2025) | $0.77 | Increased from $0.50 in Q3 2024 |
| ERC Refunds Received | $4.8M | Received in September 2025, boosting Q3 results |
| ERC Credit Not Recognized | $2.2M | Due to OBBBA for July-Sept 2021 period |
| Cash and Cash Equivalents | $25.494M | As of September 30, 2025 |
| Short-term Marketable Securities | $317.561M | As of September 30, 2025, up from $274.112M at Dec 31, 2024 |
| Cash Dividends Declared per Common Share (Q3 2025) | $0.20 | Increased from $0.16 in Q3 2024 |
| Total Revenue | $80.0M | for the six months ended June 30, 2025, up from $70.0M in 2024 |
Forward-Looking Statements
- {"claim":"George W. LeMaitre will maintain a significant ownership stake in LeMaitre Vascular, Inc.","entity":"George W. LeMaitre","targetDate":"December 31, 2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Lemaitre Vascular Inc (LMAT)?
Lemaitre Vascular Inc has 37 recent SEC filings from Jan 2024 to Apr 2026, including 16 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LMAT filings?
Across 37 filings, the sentiment breakdown is: 6 bullish, 31 neutral. The dominant sentiment is neutral.
Where can I find Lemaitre Vascular Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lemaitre Vascular Inc (LMAT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Lemaitre Vascular Inc?
Key financial highlights from Lemaitre Vascular Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LMAT?
The investment thesis for LMAT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Lemaitre Vascular Inc?
Key executives identified across Lemaitre Vascular Inc's filings include David L. Roberts, Donald Trump, David M. D’Amato, Dr. David E. Astion, George W. LeMaitre.
What are the main risk factors for Lemaitre Vascular Inc stock?
Of LMAT's 29 assessed filings, 0 were flagged high-risk, 6 medium-risk, and 23 low-risk.
What are recent predictions and forward guidance from Lemaitre Vascular Inc?
Recent forward-looking statements from Lemaitre Vascular Inc include guidance on {"claim":"George W. LeMaitre will maintain a significant ownership stake in LeMaitre Vascular, Inc.","entity":"George W..